AR034371A1 - PHARMACEUTICAL COMPOSITIONS - Google Patents
PHARMACEUTICAL COMPOSITIONSInfo
- Publication number
- AR034371A1 AR034371A1 ARP020102106A ARP020102106A AR034371A1 AR 034371 A1 AR034371 A1 AR 034371A1 AR P020102106 A ARP020102106 A AR P020102106A AR P020102106 A ARP020102106 A AR P020102106A AR 034371 A1 AR034371 A1 AR 034371A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical compositions
- ophthalmic
- eye
- day
- useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Las composiciones oftálmicas que comprende un fármaco oftálmico y un compuesto de polisacárido lineal son útiles para la adminsitración tópica una vez al día al ojo.Ophthalmic compositions comprising an ophthalmic drug and a linear polysaccharide compound are useful for topical administration once a day to the eye.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01113958 | 2001-06-08 | ||
EP01113959 | 2001-06-08 | ||
EP01115097 | 2001-06-21 | ||
EP01115096 | 2001-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034371A1 true AR034371A1 (en) | 2004-02-18 |
Family
ID=27440131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020102106A AR034371A1 (en) | 2001-06-08 | 2002-06-06 | PHARMACEUTICAL COMPOSITIONS |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1404370A2 (en) |
JP (1) | JP2005508866A (en) |
CN (1) | CN1514735A (en) |
AR (1) | AR034371A1 (en) |
AU (1) | AU2002314149A1 (en) |
BR (1) | BR0210139A (en) |
CA (1) | CA2449213A1 (en) |
PE (1) | PE20030206A1 (en) |
WO (1) | WO2002100437A2 (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002345015A1 (en) * | 2001-06-08 | 2002-12-23 | Novartis Pharma Gmbh | Ophthalmic once-a-day composition |
US8580851B2 (en) | 2002-08-21 | 2013-11-12 | Sucampo Ag | Ophthalmic solution |
JP2004143155A (en) * | 2002-10-01 | 2004-05-20 | Taisho Pharmaceut Co Ltd | Ophthalmic solution |
US20040137079A1 (en) * | 2003-01-08 | 2004-07-15 | Cook James N. | Contact lens and eye drop rewetter compositions and methods |
KR20120005052A (en) * | 2003-08-21 | 2012-01-13 | 수캄포 아게 | Ophthalmic composition |
US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
AU2005209201B2 (en) * | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
DE102005035986B4 (en) * | 2005-07-28 | 2009-10-15 | Bausch & Lomb Incorporated | Sterile drippable multiphase emulsifier-free ophthalmic preparation |
US20070077302A1 (en) * | 2005-09-30 | 2007-04-05 | Azaam Alli | Methods for stabilizing ophthalmic compositions |
CN100408046C (en) * | 2005-12-22 | 2008-08-06 | 涂家生 | Macrolide antibiotics sodium hyaluronate eye transfer system |
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
US20090143348A1 (en) * | 2007-11-30 | 2009-06-04 | Ahmet Tezel | Polysaccharide gel compositions and methods for sustained delivery of drugs |
CA2813734A1 (en) * | 2010-10-04 | 2012-04-12 | Activbiotics Pharma, Llc | Use of rifalazil and analogues thereof to treat ocular disorders |
KR101412776B1 (en) * | 2013-03-11 | 2014-07-01 | 가톨릭대학교 산학협력단 | Eye drop composition for treating keratoconjunctivitis and preparation method of the same |
US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10617763B2 (en) | 2013-08-28 | 2020-04-14 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US10064818B2 (en) | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
US9833441B2 (en) | 2013-08-28 | 2017-12-05 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US11179327B2 (en) | 2013-08-28 | 2021-11-23 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
US9320709B2 (en) | 2013-08-28 | 2016-04-26 | Presbyopia Therapies Llc | Storage stable compositions and methods for the treatment of refractive errors of the eye |
US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
US9844537B2 (en) | 2013-08-28 | 2017-12-19 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
US10307408B2 (en) | 2013-08-28 | 2019-06-04 | Presbyopia Therapies, LLC | Contact lens compositions and methods for the treatment of presbyopia |
BR112019002967A2 (en) | 2016-08-19 | 2019-05-14 | Orasis Pharmaceuticals Ltd. | ophthalmic pharmaceutical composition, methods of correcting presbyopia, reducing pupil size, inducing miosis, increasing depth of field, decreasing the magnitude of higher order aberrations, and improving near and far uncorrected visual acuity , implant and kit. |
US11648247B1 (en) | 2021-12-16 | 2023-05-16 | Lenz Therapeutics, Inc. | Compositions and methods for the treatment of presbyopia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1229075B (en) * | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Topical compsn. contg. hyaluronic acid deriv. as vehicle |
RU2089191C1 (en) * | 1994-01-28 | 1997-09-10 | Научно-производственная фирма "Нарт" | Method of prolongation of physiological effect of thymolol with respect to intraocular pressure decreasing |
CA2193149C (en) * | 1995-12-22 | 2002-04-23 | David H. Donabedian | Cationic therapuetic agents and delivery systems |
JPH1160505A (en) * | 1997-05-20 | 1999-03-02 | Senju Pharmaceut Co Ltd | Antiseptic composition |
DE19923829A1 (en) * | 1999-05-17 | 2000-11-23 | Ulrich Kluegel | Complex of hyaluronate, active ingredient and water, useful as topical pharmaceutical or cosmetic composition, is stable and has high content of active agent |
US6777429B1 (en) * | 1999-07-23 | 2004-08-17 | Novartis Ag | Ophthalmic composition |
-
2002
- 2002-06-06 AR ARP020102106A patent/AR034371A1/en unknown
- 2002-06-07 WO PCT/EP2002/006279 patent/WO2002100437A2/en not_active Application Discontinuation
- 2002-06-07 CA CA002449213A patent/CA2449213A1/en not_active Abandoned
- 2002-06-07 AU AU2002314149A patent/AU2002314149A1/en not_active Abandoned
- 2002-06-07 JP JP2003503256A patent/JP2005508866A/en active Pending
- 2002-06-07 CN CNA028115317A patent/CN1514735A/en active Pending
- 2002-06-07 PE PE2002000483A patent/PE20030206A1/en not_active Application Discontinuation
- 2002-06-07 EP EP02740697A patent/EP1404370A2/en not_active Withdrawn
- 2002-06-07 BR BR0210139-4A patent/BR0210139A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2002314149A1 (en) | 2002-12-23 |
CN1514735A (en) | 2004-07-21 |
EP1404370A2 (en) | 2004-04-07 |
CA2449213A1 (en) | 2002-12-19 |
WO2002100437A2 (en) | 2002-12-19 |
JP2005508866A (en) | 2005-04-07 |
WO2002100437A3 (en) | 2003-04-24 |
PE20030206A1 (en) | 2003-04-09 |
BR0210139A (en) | 2004-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034371A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
RS51569B (en) | Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol | |
DE60205749D1 (en) | ORAL DRUG COMPOSITIONS TO BE APPLIED WITH A TAXED ACTIVE SUBSTANCE | |
AR035293A1 (en) | OPHTHALMIC COMPOSITION. | |
NO2011025I1 (en) | Telavancin, or a pharmaceutically acceptable salt thereof, including including telavancin hydrochloride | |
AR005703A1 (en) | SUBSTITUTED OXAZOLIDINONES, PROCEDURE FOR THE PREPARATION, USE OF THE SAME TO PREPARE MEDICINES AND MEDICINES THAT CONTAIN THEM | |
CO5050297A1 (en) | USE OF PEG-IFN-ALFA AND RIBAVIRINE FOR THE TREATMENT OF CHRONIC HEPATITIS C | |
CR7921A (en) | PALONOSETRON LIQUID PHARMACEUTICAL FORMULATIONS | |
AR034213A1 (en) | COMPOSITIONS OF DRUGS ON THE BASE OF ANTI-POLINERGIC AGENTS AND INHIBITORS OF PDE-IV | |
EE200300311A (en) | Phthalazinone-piperidine derivatives, their use and medicine | |
TR200201174T2 (en) | Pharmaceutical compositions containing fluoroquinolone antibiotic medicine and xanthan gum. | |
DE60327693D1 (en) | TOPICAL COMPOSITION CONTAINING A CYCLOFRUCTAN, A CARRIER AND A MEDICAMENT | |
DE69923336D1 (en) | ORANGE BUPRENORPHINIC MEDICINAL PRODUCTS TO BE APPLIED | |
CR6834A (en) | COMPLEXES AND COMPOSITIONS OF MACROMOLECULAR DRUGS CONTAINING THE SAME | |
HRP20070291T3 (en) | Pharmaceutical composition comprising a zinc-hyaluronate complex for the treatment of multiple sclerosis | |
BRPI0611526A2 (en) | topical composition containing gelatin | |
AR034372A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
DE60309832D1 (en) | OSMOTIC ADMINISTRATION SYSTEM | |
EE200300129A (en) | Use of distamycin alpha-haloacryloyl derivative | |
DE60217315D1 (en) | PHARMACEUTICAL COMPOSITIONS OF RAPAMYCINES | |
DE60111503D1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING TERBINAFIN | |
DE60312642D1 (en) | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE | |
ITMI20020872A1 (en) | HYPERPHORINE DERIVATIVES THEIR USE AND FORMULATIONS CONTAINING THEM | |
SV2003001422A (en) | "1,3-DIARILPROP-2-EN-1-ONAS, COMPOSITIONS THAT CONTAIN THEM AND ITS USE" | |
ITMI20020921A1 (en) | DRUG ADMINISTRATION DEVICE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |